UNCY

Unicycive TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

Peers tracked

U.S. public peers

Grade Position

Below peers

vs peer average

UNCY vs peer average

28/100

UNCY vs. peer average (F vs. D)

Grade spread

B 4 · D 2 · F 4

Graded peers loaded

Coverage

10 graded

100% of tracked

Peer overview

ARDX is the first available peer comparator.

Direct operating comparator: Unicycive identifies Ardelyx's FDA-approved Xphozah as a competing hyperphosphatemia treatment, making it relevant to nephrology adoption, reimbursement, and dialysis-channel execution [#10-K-2026-03-30].

✓Peer source comes from the stored AI memo or peer model

✓Grades and factor rows use RankAlpha API data when available

✓Missing peer scores remain blank instead of being estimated

✓Side-by-side comparison keeps the data contract visible

Top peerARDXArdelyx

UNCY

Unicycive Therapeutics

ARDX

Ardelyx

Grade

Momentum

Value

Sentiment

Setup Bias

Net —

Market Cap

Posture

Defensive

Mixed

Open Side-by-Side Comparison Compare all

Grade position vs ARDX

UNCY / ARDX

Grade Position

Below peers

UNCY vs. peer average (F vs. D)

28/100

Momentum

UNCY

Value

UNCY

Sentiment

ARDX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank

Ticker

Company

Grade

Grade score

vs UNCY

ARDX

80/100

-3

AKBA

40/100

-1

KZIA

Kazia Therapeutics Ltd ADR

80/100

-3

HUMA

Humacyte Inc Common

20/100

Even

CNTB

Connect Biopharma Holdings Ltd Common

20/100

Even

ARDX is the first peer returned for this comparison set.